Navigation Links
MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
Date:9/11/2007

VANCOUVER, and SAN DIEGO, Sept. 11 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, reports financial results for the three months ended July 31, 2007 and an update on its programs.

UPDATE ON DRUG DEVELOPMENT PROGRAMS

Omiganan 1% gel (Omigard(TM)/CPI-226/MX-226; topical cationic peptide; prevention of catheter-related infections): A pivotal Phase III study is in progress in the United States under a Special Protocol Assessment (SPA) agreement with the US FDA and in Europe. This confirmatory Phase III trial is a randomized, Evaluation Committee-blinded study to assess the effectiveness of Omigard(TM) vs. 10% povidone-iodine for the prevention of central venous catheter-related infections. This ongoing trial is known as the Central Line Infection Reduction Study, or CLIRS trial.

On July 30, 2007 Cadence Pharmaceuticals, our North American and European development and commercialization partner for Omigard(TM), announced that the FDA had agreed with their plan to increase the number of patients to be enrolled in CLIRS trial from 1,250 to 1,850. Cadence also announced that in June 2007 it completed enrollment of the original target of 1,250 patients in this clinical trial. Cadence expects they will complete enrollment of the new goal of 1,850 patients in the second quarter of 2008. If the results of the CLIRS trial are positive, Cadence expects to submit an NDA for omiganan 1% gel in the first half of 2009.

Celgosivir (MX-3253; oral a-glucosidase I inhibitor; treatment of chronic hepatitis C virus infections): Final top-line results of a Phase II combination study in non-responder and partial responder patients were announced April 11, 2007, demonstrating proof-of-concept and evidence of clinical benefit when adding celgosivir to the current standard-of-care HCV therapy (pegylated interferon plus ribavirin) as compared to the active control treatment (standard-of-care
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... (PRWEB) January 21, 2015 Cambridge Semantics, the ... technology, today announced that 2014 was a record-breaking year across ... capabilities of the Anzo Smart Data Platform and our Smart ... utilize insights from diverse data which led to record growth ...
(Date:1/22/2015)... zFlo Motion , a US leader in ... product from a new partner. STT-Systems has developed ... 15 years, with offerings in the optical-motion capture, 3D scanning, ... (inertial measurement unit), iSen, is opening eyes around the world. ...
(Date:1/22/2015)... 22 de enero de 2015  El Dr. Paul ... llamada a nominaciones para 2015. Este prestigioso premio reconoce ... tiene el potencial para hacer, contribuciones destacadas para la ... hasta el 15 de marzo de 2015 a través ...
(Date:12/25/2014)... 25, 2014 The report “Service Quality ... Type & Provider Type - Global Advancements, Worldwide Forecasts ... an in-depth analysis and forecasting of revenues. , ... 221 pages and in-depth TOC on “Service Quality Management ...
Breaking Biology Technology:Cambridge Semantics Announces Record Results for 2014 23D Motion Capture Just Got Easy 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4
... - Live Webcast -- LONDON, October 29, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the first ...
... Oct. 28 Orexigen® Therapeutics, Inc. (Nasdaq: OREX ... today announced that on October 26, 2010 the Compensation Committee ... an inducement stock option to purchase 9,000 shares of common ... has an exercise price per share equal to $5.79, the ...
... ANNAPOLIS, Md., Oct. 28 PharmAthene, Inc. (NYSE Amex: ... biological and chemical threats, today announced that it intends to ... underwritten public offering. The offering is subject to market conditions ... when the offering may be completed, or as to the ...
Cached Biology Technology:Hikma Expands its Global Injectables Business - Live Webcast 2Hikma Expands its Global Injectables Business - Live Webcast 3Hikma Expands its Global Injectables Business - Live Webcast 4Hikma Expands its Global Injectables Business - Live Webcast 5Hikma Expands its Global Injectables Business - Live Webcast 6Hikma Expands its Global Injectables Business - Live Webcast 7Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 2PharmAthene Announces Proposed Common Stock Offering 2PharmAthene Announces Proposed Common Stock Offering 3
(Date:1/22/2015)... NEW YORK , Jan. 22, 2015   EyeLock, Inc. ... announced it has appointed Steve Gerber to the ... Gerber will be responsible for leading development of mobile platforms ... 25 years of success and innovation in the semiconductor industry ...
(Date:12/22/2014)... DUBLIN , Dec. 22, 2014 Research and ... the addition of the "The Global Watermarking ... http://photos.prnewswire.com/prnh/20130307/600769 ... global digital media watermarking and fingerprinting markets. Watermarking ...
(Date:12/19/2014)... Dec. 18, 2014  23andMe, Inc., the leading personal genetics company, ... differences in genetic ancestry of individuals from across ... arrived more than four hundred years ago, the ... for peoples from different continents. This study illuminates how American ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2The Global Watermarking and Fingerprinting Markets 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... Research teams at Yale University and the University of Rhode ... treat tumors using a short piece of protein that acts ... to a report in the Proceedings of the National Academy ... called “pHLIP?(pH (Low) Insertion Peptide) can be injected into the ...
... on islands around the world has confirmed what island ... islands are much more abundant than their counterparts on ... study signals an alarm for island populations in a ... have devastating consequences for lizards and other animals that ...
... have converted protein sequences into classical music in an ... of genomic biology. New research published today in the ... found a way to present human proteins as musical ... the University of California, Los Angeles, USA, have so ...
Cached Biology News:pHLIP, a novel technology to locate and treat tumors 2Global survey of lizards reveals greater abundance of animals on islands than on mainland ecosystems 2Global survey of lizards reveals greater abundance of animals on islands than on mainland ecosystems 3The sound of proteins 2